Warning: The NCBI web site requires JavaScript to function. more...
Clinical development of anti-RANKL therapy.
Schwarz EM, Ritchlin CT.
Arthritis Res Ther. 2007;9 Suppl 1:S7. Review.
Related citations
[Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K, Ito K.
Clin Calcium. 2007 Jan;17(1):37-46. Review. Japanese.
Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA.
Drugs Today (Barc). 2008 Jan;44(1):7-21. Review.
Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T, Feng X.
Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM.
Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA.
Expert Opin Biol Ther. 2009 Apr;9(4):465-79. Review. Erratum in: Expert Opin Biol Ther. 2009 May;9(5):675.
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD, Yang FS, Xuan K, Bai YX, Wu BL.
Med Hypotheses. 2008 Aug;71(2):256-8. Epub 2008 Apr 28.
RANKL inhibition in the treatment of bone metastases.
Lipton A, Jun S.
Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. Review.
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.
Prostate. 2008 Jan 1;68(1):92-104.
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
Curr Opin Investig Drugs. 2007 Apr;8(4):299-303. Review.
The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC, Chaisson M.
Cancer Metastasis Rev. 2006 Dec;25(4):541-9. Review.
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D, Maalouf NM, Sakhaee K.
J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S, Phillips JS, Sayers J, Croucher PI.
J Biol Chem. 2007 Oct 26;282(43):31601-9. Epub 2007 Aug 15.
RANK ligand: effects of inhibition.
George S, Brenner A, Sarantopoulos J, Bukowski RM.
Curr Oncol Rep. 2010 Mar;12(2):80-6. Review.
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S.
Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.
[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].
Dougall W, Chaisson M.
Clin Calcium. 2006 Apr;16(4):627- 35. Review. Japanese.
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD.
J Clin Densitom. 2008 Apr-Jun;11(2):325-38. Epub 2008 Apr 2. Review.
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD, Dougall WC.
Cancer Treat Rev. 2008 Feb;34(1):92-101. Epub 2007 Oct 26. Review.
Targeting RANK/RANKL in the treatment of solid tumours and myeloma.
Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA.
Curr Pharm Des. 2010;16(11):1272-83. Review.
Clinical applications of RANK-ligand inhibition.
Romas E.
Intern Med J. 2009 Feb;39(2):110-6. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on